FDA calendar · October 2022 · built from SEC filings

PDUFA dates October 2022: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in October 2022. The FDA calendar also recorded 19 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in October 2022

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

October 2022: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Oct 2022Month disclosedHepcludex® (bulevirtide)GILDComplete Response Letterwith hepatitis delta virus infectionCRL issuedSEC Form 10-Q
Oct 2022Month disclosedTECVAYLI (teclistamab)LEGNFDA approval—ApprovedSEC Form 10-K
October 3, 2022Aimovig (erenumab-aooe)AMGNLabel expansion—ApprovedopenFDA Drugs@FDA
October 3, 2022Kisqali Femara Co-Pack (Copackaged) (letrozole; ribociclib succinate)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
October 3, 2022KISQALI® (ribociclib)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
October 12, 2022Scemblix (asciminib)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
October 14, 2022Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
October 14, 2022Lyumjev (insulin lispro-aabc)LLYLabel expansion—ApprovedopenFDA Drugs@FDA
October 17, 2022Vemlidy (tenofovir alafenamide fumarate)GILDLabel expansion—ApprovedopenFDA Drugs@FDA
October 21, 2022RINVOQ® (upadacitinib)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
October 21, 2022Imfinzi® (durvalumab)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
October 21, 2022Imjudo (tremelimumab-actl)AZNFDA approvalTo treat unresectable hepatocellular carcinomaApprovedFDA Novel Drug Approvals
October 25, 2022Tecvayli (teclistamab-cqyv)JNJFDA approval—ApprovedFDA Novel Drug Approvals

October 2022: dated readouts

DateDrugCompanyEventIndicationStatusSource
Oct 2022Month disclosedCNM-Au8CLNNTopline readout—MixedSEC Form 10-K
Oct 2022Month disclosedCARDAMYST (etripamil)MISTTopline readout—Met primary endpointSEC Form 10-Q
Oct 2022Month disclosed—PCVXTopline readout—PositiveSEC Form 10-K
Oct 2022Month disclosedlabafenogeneSYBXTopline readout—PositiveSEC Form 10-K
Oct 2022Month disclosedXP-8121XERSTopline readout—PositiveSEC Form 10-K

October 2022: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Oct 2022Month disclosedJANX007JANXTrial startprostate cancerCompletedSEC Form 10-K

Questions

What PDUFA dates are in October 2022?

0 PDUFA dates fell in October 2022. The FDA calendar also recorded 19 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.